Posts

CureApp Hypertension Therapeutics App Clinical trial results announced at ESC Congress 2021 and published in the European Heart Journal, a leading cardiovascular journal

Image
  CureApp Hypertension Therapeutics App Clinical trial results announced at ESC Congress 2021 and published in the European Heart Journal, a leading cardiovascular journal Japan’s first major leap toward digital therapeutics in the field of hypertension The results of a Japanese Phase III domestic multicenter randomized controlled trial of a digital therapeutic app for hypertension (DTx) jointly developed by CureApp, Inc. (CEO Kohta Satake; hereafter “the Company”) and Jichi Medical University were presented by Professor Kazuomi Kario of Jichi University’s Department of Cardiovascular Medicine at the European Society of Cardiology Congress held at the end of August 2021 (ESC Congress 2021 - The Digital Experience: Late Breaking Trials in Hypertension). The results of this trial were also published in the European Heart Journal, one of the world’s leading journals on cardiovascular disease. Summary of the clinical trial  This clinical trial* 1 ran from January 2020 to December 2020 ev

CureApp and Jichi Medical University collaborate on a hypertension therapeutics app Primary endpoint met in Phase III clinical trial in Japan

Image
A major step toward realizing a groundbreaking new treatment method for hypertension — the first of its kind in Japan CureApp, Inc. (Head Office: Chuo-ku, Tokyo; CEO: Kohta Satake; hereafter “the Company”) has completed a Japanese Phase III multicenter randomized controlled trial of their digital therapeutics (“DTx”) app to treat hypertension, which was jointly researched by a team led by Professor Kazuomi Kario at Jichi Medical University. Results of this study showed a statistically significant difference in average systolic blood pressure*1 over a 24-hour period – the primary endpoint of this study, demonstrating a hypotensive effect. Moving forward, the Company will seek regulatory approval based on the results of this study. Summary of the clinical trial and efficacy of the hypertension therapeutics app  Commencing in December 2019, this trial*2 evaluated the efficacy and safety of the DTx app when used with patients with essential hypertension who had not received oral treatments

CureApp SC, Digital Therapeutic for Nicotine Addiction: Introducing a New Form of App-based Prescription Treatment Reimbursed in Japan’s Public Healthcare Insurance System

Image
CureApp SC, Digital Therapeutic for Nicotine Addiction: Introducing a New Form of App-based Prescription Treatment Reimbursed in Japan’s Public Healthcare Insurance System -  The Firs t Digital Therapeutic  to Be Covered by Japan’s Public Healthcare Insurance System CureApp, Inc. (Headquarters: Chuo-ku, Tokyo; CEO: Kohta Satake) has announced that CureApp SC Nicotine Addiction Treatment App and CO Checker (hereafter, CureApp SC) – a treatment app(digital therapeutic) targeting nicotine addiction – is now covered by Japan’s public healthcare insurance system as of December 1, 2020, following a period of clinical trials and regulatory approval. This marks the first case of a digital therapeutics application being covered by the insurance, as well as the first time that a digital therapeutic in the field of smoking cessation treatments has been covered by a country’s national health insurance system in the world. Patients diagnosed with nicotine addiction at a medical institution are elig

【Publication information】 Nicotine Addiction Treatment App With CO Checker Receives Regulatory Approval - CureApp, Inc.

Image
We are pleased to inform you that the article has been published with the approval of our Nicotine Addiction Treatment App With CO Checker.   Bio Space Asia’s First Prescription “Digital Therapeutic” Approved in Japan; Nicotine Addiction Treatment App With CO Checker Receives Regulatory Approval - CureApp, Inc.   https://www.biospace.com/article/releases/asia-s-first-prescription-digital-therapeutic-approved-in-japan-nicotine-addiction-treatment-app-with-co-checker-receives-regulatory-approval-cureapp-inc-/?s=85&utm_source=dlvr.it&utm_medium=twitter

Asia’s First Prescription “Digital Therapeutic” Approved in Japan ; Nicotine Addiction Treatment App with CO Checker Receives Regulatory Approval

Image
  Entering a New Age Where Innovative Treatments Are Provided With an App Asia’s First Prescription “Digital Therapeutic” Approved in Japan Nicotine Addiction Treatment App with CO Checker Receives Regulatory Approval The World’s First App-based Nicotine Addiction Treatment     CureApp, Inc. (Headquarter: Chuo-ku, Tokyo; CEO: Kohta Satake) received regulatory authorization for the manufacturing and sale of Asia’s first therapeutics app, the “CureApp SC Nicotine Addiction Treatment App and CO Checker” (hereafter, CureApp SC), from the Ministry of Health, Labour and Welfare (MHLW) on August 21st, 2020. The Company is currently proceeding with plans to receive insurance reimbursement and release CureApp SC in FY2020. CureApp SC  CureApp SC is a prescription medical device designed to aid patients who are receiving outpatient smoking cessation treatment. The device supports patients in their attempt to quit smoking in a home setting.  The product consists of three components - a patient ap

CureApp Named to the 2020 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups

Image
CureApp Named to the 2020 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups  CureApp recognized for achievements in develop evidence-based medical programs, “Digital Therapeutics (DTx),” for patients who suffer from conditions that conventional treatment methods with drugs or devices were not effective   NEW YORK, August 13, 2020 -- CB Insights today named CureApp to its second annual Digital Health 150 ranking, which showcases the 150 most promising private digital health companies in the world. The 2020 Digital Health 150 cohort highlights startups that are reimagining the lines of the traditional healthcare experience across 12 categories, from Virtual Care Delivery and Clinical Trials, to Drug Discovery and Specialty Care. Countries represented this year include Canada, China, Israel, France, the United Kingdom, and the United States, among others. “This year’s Digital Health 150 is our most global ever, covering the best private healthcare compa

【Publication information】"Digital Therapeutics will Become a Major Treatment Option in the Future: Kohta Satake, CEO of CureApp."

Image
We are pleased to inform you that our article has been published on Smart Industry News titled "Digital Therapeutics will Become a Major Treatment Option in the Future: Kohta Satake, CEO of CureApp." https://www.smartindustrynews.com/sin-article/digital-therapeutics-will-become-a-major-treatment-option-in-the-future-kohta-satake-ceo-of-cureapp/